ArticleDigital health
Development and validation of an interpretable machine learning model for predicting hypertension risk in patients with psoriasis.
Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Hypertension is a common yet frequently underdiagnosed comorbidity in psoriasis patients. Early identification and blood pressure control are critical to improving outcomes. Although machine learning (ML) is widely used in disease prediction, a model for hypertension risk within the psoriasis population remains unavailable. This study aims to develop and validate such a model in patients with psoriasis. Methods: In this retrospective study, 2,957 psoriasis patients from a single tertiary center were used for model development and internal validation, and 567 psoriasis participants from the National Health and Nutrition Examination Survey (NHANES) served as the external validation cohort. After missForest imputation and consensus feature selection, the Synthetic Minority Oversampling Technique (SMOTE) was applied to the training set only. Nine machine learning algorithms were trained and evaluated for discrimination, calibration, and clinical utility. Shapley Additive Explanations (SHAP) were used for model interpretation. Results: Nine nonredundant predictors were retained. The SMOTE-enhanced logistic regression model showed the most balanced and generalizable performance, with area under the receiver operating characteristic curve values of 0.850, 0.816, and 0.789 in the training, internal validation, and external validation cohorts, respectively, together with acceptable calibration and favorable net clinical benefit. SHAP identified age, dyslipidemia, and type 2 diabetes mellitus as the leading contributors. The final model was deployed as a publicly accessible web application. Conclusions: This interpretable and externally validated machine learning model provides a practical tool for hypertension risk stratification in psoriasis patients and may support earlier identification and individualized preventive management in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.